By the end of 2001 the world market for recombinant human erythropoietin (rHuEpo) was valued at $5.3 billion, a growth of 12% over 2000. The market has been growing at an 11% average annual growth rate over the previous 5 years.   

Based on quarterly sales figures from participating companies, the market in 2002 is expected to reach US$5.9 billion a 12% growth over 2001. 

The strategic landscape of the market is changing rapidly. In 2001 Roche completed its acquisition of Chugai thus consolidating its position in the market and Amgen launched Aranesp, darbpoetin alfa, as a second-generation product. 

During the same year Baxter acquired the rights to Epomax, Elanex's epoetin omega which is marketed in 15 countries outside the US and Aventis started the process of launching Dynepo, a gene-activated-erythropoietin from Transkaryotic therapies. Generics have already entered the markets of South East Asia. 

Erythropoietin, State-of-the-Science & Strategic Opportunities is a strategic consulting report that assesses both the technology status and the competitive landscape of the r-HuEpo market. The report examines both the US and the European markets, profiles leading products and companies and offer revenue forecasts to the year 2007.  The report assesses the market attractiveness and potential and evaluates different options for market entry. 

Report Code: ASI021110

Report Price: US$680 Hard Copy (including shipping & handling), US$480 PDF Format (delivered by email)

Date Published:  November 2002

Number of Pages:  30 

Publisher: AS Insights Opportunity and Valuation Reports 

To order go to this URL: http://www.bioportfolio.com/cgi-bin/acatalog/Bioportfolio_AS_Insights_Opportunity_and_Valuation_Reports__10.html#a236